Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

ARCT


Top 10 Correlated ETFs

ARCT


Top 10 Correlated Stocks

ARCT


In the News

09:11 29 Nov 2022 ARCT

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Kyle Gutsadt - Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Padmanabh Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Seamus Fernandez - Guggenheim Yigal Nochomovitz - Citi Pete Stavropoulos - Cantor Fitzgerald Yale Jen - Laidlaw and Company Yanan Zhu - Wells Fargo Securities Operator Good day ladies and gentlemen and welcome to the Arcturus Therapeutics Third Quarter 2022 Earnings Call. Today's conference is being recorded.

06:48 29 Nov 2022 ARCT

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

05:00 29 Nov 2022 ARCT

Arcturus Therapeutics to Present at the Following Investor Conferences in November

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.

06:47 29 Nov 2022 ARCT

Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

12:00 29 Nov 2022 ARCT

Why Arcturus Therapeutics Stock Is Skyrocketing Today

Investors are applauding Arcturus' collaboration with CSL.

11:06 29 Nov 2022 ARCT

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?

A strategic collaboration has today's traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a wide variety of applications.

06:00 29 Nov 2022 ARCT

Arcturus Therapeutics to Attend the Following Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences. Jefferies Cell and Genetic Medicine Summit (Attending) Thursday – Friday, September 29 – 30, 2022 Cantor Neurology &am

12:28 29 Nov 2022 ARCT

7 Small-Cap Stocks to Buy on the Dip or You'll Be Kicking Yourself Later

With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tethered to small-capitalization companies, these market ideas don't always grab the spotlight.

10:41 29 Nov 2022 ARCT

Acrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call Transcript

Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientifc Officer and Chief Operating Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Nick Abbott - Wells Fargo Kumaraguru Raja - Brookline Capital Markets Yale Jen - Laidlaw and Company Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Operator Good day and welcome to the Arcturus Therapeutics Second Quarter 2022 Financial Update and Pipeline Progress Call. Today's conference is being recorded.

06:48 29 Nov 2022 ARCT

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Financial details

Company Rating
Buy
Market Cap
436.6M
Income
-179.18M
Revenue
26.84M
Book val./share
5.5
Cash/share
8.98
Dividend
-
Dividend %
-
Employees
177
Optionable
No
Shortable
Yes
Earnings
09 Nov 2022
P/E
-2.19
Forward P/E
-2.01
PEG
-0.24
P/S
16.25
P/B
2.99
P/C
1.79
P/FCF
-2.25
Quick Ratio
3.16
Current Ratio
3.25
Debt / Equity
0.43
LT Debt / Equity
0.43
-
-
EPS (TTM)
-6.79
EPS next Y
-7.99
EPS next Q
-2.49
EPS this Y
118.03%
EPS next Y
17.6%
EPS next 5Y
17.6%
EPS last 5Y
17%
Revenue last 5Y
-1%
Revenue Q/Q
154.94%
EPS Q/Q
-31.44%
-
-
-
-
SMA20
5.52%
SMA50
7.69%
SMA100
-1.58%
Inst Own
83.95%
Inst Trans
-0.04%
ROA
-61%
ROE
-88%
ROC
-0.82%
Gross Margin
-
Oper. Margin
-666%
Profit Margin
-667%
Payout
-
Shs Outstand
26.58M
Shs Float
22.91M
-
-
-
-
Target Price
19.5
52W Range
11.7-48.75
52W High
-66.48%
52W Low
+46.27%
RSI
41
Rel Volume
0.54
Avg Volume
548.61K
Volume
296.83K
Perf Week
-7.85%
Perf Month
12.52%
Perf Quarter
-17.66%
Perf Half Y
-19.06%
-
-
-
-
Beta
2.54649
-
-
Volatility
0.47%, 2.55%
Prev Close
-2.37%
Price
16.09
Change
-1.23%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
4.211.561.720.470.47
Net income per share
-3.53-2.16-2.15-3.55-7.74
Operating cash flow per share
-0.15-2.06-0.53-2.11-5.13
Free cash flow per share
-0.23-2.21-0.6-2.2-5.26
Cash per share
15.733.655.9122.814.08
Book value per share
10.951.352.1419.538.67
Tangible book value per share
10.951.352.1419.538.67
Share holders equity per share
10.951.352.1419.538.67
Interest debt per share
0.0511.380.861.89
Market cap
24.7M50.35M124.91M1.47B586.87M
Enterprise value
-269K23.55M69.38M1.03B266.01M
P/E ratio
-2.27-2.31-4.81-20.39-2.88
Price to sales ratio
1.93.26.01154.2447.49
POCF ratio
-53.69-2.43-19.38-34.33-4.35
PFCF ratio
-34.73-2.26-17.2-32.99-4.24
P/B Ratio
0.733.694.843.712.57
PTB ratio
0.733.694.843.712.57
EV to sales
-0.021.493.34107.4721.52
Enterprise value over EBITDA
0.03-1.12-2.84-14.55-1.31
EV to operating cash flow
0.58-1.13-10.77-23.92-1.97
EV to free cash flow
0.38-1.06-9.55-22.98-1.92
Earnings yield
-0.44-0.43-0.21-0.05-0.35
Free cash flow yield
-0.03-0.44-0.06-0.03-0.24
Debt to equity
00.730.580.030.2
Debt to assets
0.350.690.690.170.42
Net debt to EBITDA
2.411.282.276.331.58
Current ratio
4.613.333.489.453.81
Interest coverage
-69.95-117.26-29.87-86.070
Income quality
0.040.950.250.590.66
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.581.310.612.433.35
Research and developement to revenue
1.221.081.626.0614.06
Intangibles to total assets
00000
Capex to operating cash flow
0.550.070.130.040.03
Capex to revenue
-0.02-0.09-0.04-0.18-0.28
Capex to depreciation
-0.61-2.54-1.2-1.98-2.85
Stock based compensation to revenue
0.170.080.10.712.34
Graham number
29.498.1210.1839.5138.86
ROIC
-0.26-0.69-0.42-0.17-0.69
Return on tangible assets
-0.21-0.49-0.32-0.15-0.52
Graham Net
9.950.941.3818.947.92
Working capital
39.83M29.25M52.97M418.27M279.42M
Tangible asset value
00000
Net current asset value
32.64M11.27M17.94M387.89M214.36M
Invested capital
00.730.610.040.22
Average receivables
1.3M3.3M2.15M2.13M2.75M
Average payables
6.28M6.59M8.28M10.77M10.42M
Average inventory
00000
Days sales outstanding
13.48103.8338.2681.3199.44
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
27.083.529.544.493.67
Payables turnover
00000
Inventory turnover
00000
ROE
-0.32-1.6-1.01-0.18-0.89
Capex per share
-0.08-0.15-0.07-0.09-0.13

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-09-30
Revenue per share
0.080.090.220.20.51
Net income per share
-2.07-2.05-1.47-1.94-1.33
Operating cash flow per share
-1.25-0.63-1.61-1.86-2.99
Free cash flow per share
-1.27-0.7-1.65-1.94-3.06
Cash per share
16.4715.7114.0612.128.98
Book value per share
11.619.848.6675.5
Tangible book value per share
11.619.848.6675.5
Share holders equity per share
11.619.848.6675.5
Interest debt per share
2.612.581.882.653.44
Market cap
890.77M1.26B975.55M711.1M392.24M
Enterprise value
525.29M911.79M654.69M460.62M245.52M
P/E ratio
-4.08-5.82-6.31-3.47-2.78
Price to sales ratio
445.16516.38168.37135.629.34
POCF ratio
-27.04-75.57-22.96-14.5-4.95
PFCF ratio
-26.71-68.32-22.37-13.9-4.84
P/B Ratio
2.914.864.273.852.69
PTB ratio
2.914.864.273.852.69
EV to sales
262.52374.15112.9987.8418.37
Enterprise value over EBITDA
-9.8-17.18-17.07-9.17-7.11
EV to operating cash flow
-15.95-54.75-15.41-9.39-3.1
EV to free cash flow
-15.75-49.5-15.01-9.01-3.03
Earnings yield
-0.06-0.04-0.04-0.07-0.09
Free cash flow yield
-0.04-0.01-0.04-0.07-0.21
Debt to equity
0.20.180.20.230.43
Debt to assets
0.320.40.420.460.5
Net debt to EBITDA
6.826.538.374.994.25
Current ratio
6.193.563.813.053.25
Interest coverage
-75.66-75.70-70.170
Income quality
0.60.311.10.962.25
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
5.024.461.872.050.93
Research and developement to revenue
22.8318.635.638.562.82
Intangibles to total assets
00000
Capex to operating cash flow
0.010.110.030.040.02
Capex to revenue
-0.2-0.72-0.19-0.4-0.14
Capex to depreciation
-1.41-6.11-3.61-9.42-2.4
Stock based compensation to revenue
3.772.821.31.411.25
Graham number
23.2721.3216.917.4912.85
ROIC
-0.14-0.17-0.13-0.21-0.17
Return on tangible assets
-0.12-0.12-0.1-0.15-0.12
Graham Net
11.099.117.916.263.45
Working capital
367.27M302.73M279.42M219.7M170.83M
Tangible asset value
00000
Net current asset value
294.87M245.56M214.36M169.77M98.72M
Invested capital
0.220.260.220.370.62
Average receivables
2.93M2.85M3.53M3.69M2.87M
Average payables
10.05M9.14M10.04M10.01M13.99M
Average inventory
00000
Days sales outstanding
97.2974.4252.363.3513.76
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.931.211.721.426.54
Payables turnover
00000
Inventory turnover
00000
ROE
-0.18-0.21-0.17-0.28-0.24
Capex per share
-0.02-0.07-0.04-0.08-0.07

Frequently Asked Questions

What is Arcturus Therapeutics Holdings Inc. stock symbol ?

Arcturus Therapeutics Holdings Inc. is a US stock , located in San diego of California and trading under the symbol ARCT

Is Arcturus Therapeutics Holdings Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $23. The lowest prediction is $14 and the highest is $30

What is ARCT stock prediction ?

With a median analyst target price of $25, 1 stock analysts have made 1 forecasts in last 90 days. $25 is the lowest and $25 is the greatest projection.

What is Arcturus Therapeutics Holdings Inc. stock quote today ?

Arcturus Therapeutics Holdings Inc. stock price is $16.09 today.

Is Arcturus Therapeutics Holdings Inc. stock public?

Yes, Arcturus Therapeutics Holdings Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap